Verndari, Inc., a biotechnology company based in Northern California, aims to transform global health through next generation vaccine development and delivery.
@VerndariInc is a proud finalist in the CBRN Innovation Challenge at #TechConnect2023. Pleased to share our VaxiPatch™ novel vaccine delivery technology that enhances the accessibility and performance of vaccines for greater global health equity. #healthequity#vaccines
Now published in Vaccine journal, a new article describes strong immune responses and the thermostable capabilities of the Verndari VaxiPatch™, a novel microarray patch vaccine delivery platform. Read more https://t.co/eo1gPxSyLV
@ElsevierNews @ImmunologyNews @UCDavisResearch
Verndari CEO and chief scientific officer, Daniel Henderson, believes this discovery will prove instrumental for healthcare leaders striving to overcome the various hurdles impeding universal access to COVID-19 #vaccines and more.
Learn more:
https://t.co/v25nj7kB9d (3/3)
We are pleased to announce a breakthrough mRNA stabilization discovery.
Findings announced by Verndari at World Vaccine and Immunotherapy Congress West Coast may help overcome technical, economic and political hurdles to global COVID-19 #vaccine distribution. 🧵 (1/3)
Using Verndari’s proprietary formulation, we are able to dry, store at room temperature and reconstitute 100% of the activity of mRNA vaccines in vitro.
These patent-pending formulations have the potential for use with all mRNA vaccines, therapeutics & delivery methods. (2/3)
How can using multiple adjuvants increase the immunogenic response the human body has to a vaccine antigen? Let us show you. Check out this research that uses the combined power of Avanti's 3D-PHAD and Croda's QS-21! https://t.co/2OPh7kA5EL
"There’s nothing more gratifying than being able to combine something you really care about with the goal of making an impact on the world.”
Amy Van Prooyen, Esq., is a @usflaw alum and our VP of corp. comm. & legal affairs. Learn more about her background and current role.
A pioneer in litigation communication, Amy Van Prooyen '99 wears multiple hats as head of corporate & legal affairs @VerndariInc, a biotech startup. Verndari has developed an intradermal patch that can administer vaccine thru tiny microneedles. Read more: https://t.co/ugSaEyw7DD
A pioneer in litigation communication, Amy Van Prooyen '99 wears multiple hats as head of corporate & legal affairs @VerndariInc, a biotech startup. Verndari has developed an intradermal patch that can administer vaccine thru tiny microneedles. Read more: https://t.co/ugSaEyw7DD
.@StartUsInsights included Verndari's VaxiPatch™ in its top 5 #Vaccine Distribution Solutions.
Verndari is a California-based #healthtech startup that develops VaxiPatch, a complete single-dose vaccination kit with antigen and delivery systems. https://t.co/AWPhTyIFaO (1/3)
The thermostable #VaxiPatch eliminates the need for cold chains and uses a painless #microneedle patch application for vaccine delivery via the skin.
This easy-to-use vaccine technology can potentially be self-applied and is dose-sparing. (2/3)
Verndari is proud to announce that we were selected as a quarterfinalist in the #UCSFHealthAwards2021!
Our VaxiPatch — a painless and easy-to-use microarray patch (MAP) system — is transforming the future of #vaccines. Thank you to @ucsfhealthaward for the recognition!
Congratulations to all quarterfinalists on reaching this milestone on the path to winning a coveted UCSF Health Award. Meet and learn about all the quarterfinalists through the full list here: https://t.co/UjbFcP10KE
#UCSFHealthAwards2021#quarterfinals
💉 Efficient #Vaccine distribution is crucial to achieve #HerdImmunity. US-based startup Verndari, for example, develops a complete single-dose vaccination kit. Explore more solutions addressing the topic 👉 https://t.co/cPBl5LFyzT ft. @ideabatic@StaTwig@VerndariInc#Pharma
Research underway at @UCDavis provides a window into the #COVID19 vaccine world from development to testing—including the testing of our #VaxiPatch™. @VerndariInc's innovative thermostable and painless microneedle patch is transforming #vaccine delivery. https://t.co/2z3DltnOFp
.@VerndariInc is proud to be among the Bay Area innovators addressing #COVID19. @sfchronicle highlights how our #VaxiPatch™ microneedle patch could serve as a 'shelter in place' delivery system strategy—mailable, thermostable and self-administered. https://t.co/VplweU34LI
Our @VerndariInc VaxiPatch™ and the other alternative #vaccine technologies for which @BARDA recently announced its support have something important in common—they're themostable, making them easier to store and deliver. #COVID19 https://t.co/4PN2CFuPvM
.@VerndariInc is partnering with @BARDA to accelerate work on our VaxiPatch™ dermal #vaccine delivery patch. Today, only four companies nationally received DRIVe program support to develop alternative technologies for infectious diseases such as #COVID19.